BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22814328)

  • 1. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal.
    Tsapepas DS; Mohan S; Tanriover B; Dube G; Crew RJ; Cohen DJ; Hardy MA; Sandoval PR; Ratner LE
    Transplantation; 2012 Aug; 94(4):325-30. PubMed ID: 22814328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
    Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
    Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
    Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A
    Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.
    Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM
    Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras.
    Rogers CC; Asipenko N; Horwedel T; Gautam S; Goldfarb-Rumyantzev AS; Pavlakis M; Johnson SR; Karp SJ; Evenson A; Khwaja K; Hanto DW; Mandelbrot DA
    Am J Nephrol; 2013; 38(5):397-404. PubMed ID: 24192457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.
    Stevens RB; Mercer DF; Grant WJ; Freifeld AG; Lane JT; Groggel GC; Rigley TH; Nielsen KJ; Henning ME; Skorupa JY; Skorupa AJ; Christensen KA; Sandoz JP; Kellogg AM; Langnas AN; Wrenshall LE
    Transplantation; 2008 May; 85(10):1391-9. PubMed ID: 18497677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
    Klem P; Cooper JE; Weiss AS; Gralla J; Owen P; Chan L; Wiseman AC
    Transplantation; 2009 Oct; 88(7):891-6. PubMed ID: 19935460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
    Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
    Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
    Esposito L; Kamar N; Durand D; Rostaing L
    Transplant Proc; 2005 Mar; 37(2):892-4. PubMed ID: 15848567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial.
    Eason JD; Loss GE; Blazek J; Nair S; Mason AL
    Liver Transpl; 2001 Aug; 7(8):693-7. PubMed ID: 11510013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO
    Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy.
    Laftavi MR; Patel S; Soliman MR; Alnimri M; Kohli R; Said M; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):466-8. PubMed ID: 21440735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.
    Stevens RB; Foster KW; Miles CD; Lane JT; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Nielsen KJ; Skorupa JY; Kellogg AM; Malik T; Wrenshall LE
    Transplantation; 2015 Jan; 99(1):197-209. PubMed ID: 25083614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithymocyte globulin dosing effects on biopsy-proven acute rejection and infection risk.
    Tenney JW; Mokaddem S; Shah V; Adekile A
    Ann Transplant; 2015 May; 20():285-9. PubMed ID: 25994122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.